Clinical, public health, and research implications of the heart outcomes prevention evaluation (hope) study

European Heart Journal

Volumn 22, Issue 2, 2001, Pages 103-104

  Yusuf, S ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE PREDISPOSITION; EDITORIAL; HEALTH PROGRAM; HEALTH PROMOTION; HIGH RISK POPULATION; MEDICAL RESEARCH; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH; RISK FACTOR;

CARDIOVASCULAR DISEASES; EVALUATION STUDIES; HUMANS; PUBLIC HEALTH; RAMIPRIL; RESEARCH; TREATMENT OUTCOME; VITAMIN E;

EID: 0034929941     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2000.2459     Document Type: Editorial

References (9)

1. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
2. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
3. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
4. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection
5. Results of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE)
6. Reduction of events by ramipril in high-risk subjects is largely unrelated to blood pressure decrease
7. Calcium channel blockers in acute myocardial infarction and unstable angina: An overview
8. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers
9. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial